Tianjin Chase Sun Pharmaceutical Co Ltd (300026) — Financial Flexibility Index
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has a Financial Flexibility Index of 0.09x as of September 2025. Free cash flow of CN¥174.88 Million (operating CF CN¥153.30 Million minus capex CN¥21.58 Million) represents 0% of total liabilities (CN¥1.96 Billion). Also explore 300026 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Tianjin Chase Sun Pharmaceutical Co Ltd Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Tianjin Chase Sun Pharmaceutical Co Ltd across 19 annual periods. Check how strategically is Tianjin Chase Sun Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Year-by-year free cash flow to debt coverage for Tianjin Chase Sun Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see Tianjin Chase Sun Pharmaceutical Co Ltd market capitalisation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.44x | CN¥1.05 Billion | CN¥852.24 Million | CN¥2.37 Billion | ▼ -30.2% |
| 2023 | 0.63x | CN¥1.88 Billion | CN¥1.53 Billion | CN¥2.97 Billion | ▲ +74.0% |
| 2022 | 0.36x | CN¥1.52 Billion | CN¥745.35 Million | CN¥4.17 Billion | ▲ +24.3% |
| 2021 | 0.29x | CN¥1.07 Billion | CN¥391.60 Million | CN¥3.65 Billion | ▲ +7.2% |
| 2020 | 0.27x | CN¥760.44 Million | CN¥196.66 Million | CN¥2.79 Billion | ▼ -54.2% |
| 2019 | 0.60x | CN¥807.12 Million | CN¥216.10 Million | CN¥1.36 Billion | ▼ -20.9% |
| 2018 | 0.75x | CN¥683.09 Million | CN¥388.19 Million | CN¥907.61 Million | ▼ -38.5% |
| 2017 | 1.22x | CN¥1.13 Billion | CN¥742.38 Million | CN¥919.62 Million | ▲ +76.1% |
| 2016 | 0.69x | CN¥863.60 Million | CN¥448.08 Million | CN¥1.24 Billion | ▲ +138.7% |
| 2015 | 0.29x | CN¥344.35 Million | CN¥121.00 Million | CN¥1.18 Billion | ▼ -39.3% |
| 2014 | 0.48x | CN¥328.31 Million | CN¥149.94 Million | CN¥684.85 Million | ▼ -1.3% |
| 2013 | 0.49x | CN¥250.79 Million | CN¥143.60 Million | CN¥516.40 Million | ▼ -46.0% |
| 2012 | 0.90x | CN¥373.38 Million | CN¥152.21 Million | CN¥415.19 Million | ▲ +7.8% |
| 2011 | 0.83x | CN¥298.15 Million | CN¥35.64 Million | CN¥357.47 Million | ▼ -4.5% |
| 2010 | 0.87x | CN¥159.14 Million | CN¥46.25 Million | CN¥182.14 Million | ▼ -36.2% |
| 2009 | 1.37x | CN¥184.88 Million | CN¥135.06 Million | CN¥134.90 Million | ▼ -0.3% |
| 2008 | 1.38x | CN¥126.01 Million | CN¥77.74 Million | CN¥91.63 Million | ▲ +100.9% |
| 2007 | 0.68x | CN¥77.88 Million | CN¥72.01 Million | CN¥113.79 Million | ▲ +1230.2% |
| 2006 | 0.05x | CN¥4.34 Million | CN¥1.22 Million | CN¥84.34 Million | — |